Eli Lilly and Company: Carcinoma, Hepatocellular trials
The registry lists 13 Carcinoma, Hepatocellular studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 1 7Phase 2 7Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY3435151 in Participants With Solid TumorsTerminatedNCT04099277Phase 1Results posted
- A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-FetoproteinCompletedNCT02435433Phase 3Results posted
- A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedNCT02423343Phase 1/2Results posted
- A Study of LY2157299 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02178358Phase 2Results posted
- A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver CancerCompletedNCT02069041Phase 1Results posted
- A Study of LY2157299 in Participants With Hepatocellular CarcinomaCompletedNCT01246986Phase 2Results posted
- A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With SorafenibCompletedNCT01140347Phase 3Results posted
- A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the LiverCompletedNCT00906373Phase 2Results posted
- Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With ChemotherapyCompletedNCT00627042Phase 2Results posted
- A Study of LY3200882 and Pembrolizumab in Participants With Advanced CancerWithdrawnNCT04158700Phase 1/2
- A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesCompletedNCT02572687Phase 1
- A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)CompletedNCT02240433Phase 1
- A Study of LY2181308 in Patients With Advanced Hepatocellular CarcinomaWithdrawnNCT00415155Phase 1/2